33 results about "Alfuzosin" patented technology

A monolithic composition includes alfuzosin in a polymeric matrix adapted to release 13-33% of the alfuzosin within 2 hours, 40-60% of the alfuzosin within 7 hours, and greater than 80% of the alfuzosin within 20 hours of administration. A unit dosage form includes: a heterogeneous mixture of alfuzosin hydrochloride anhydrate, lactose monohydrate, hydroxypropylmethylcellulose, polyvinylpyrrolidone and magnesium stearate, wherein the heterogeneous mixture is heterogeneously distributed throughout the unit dosage form. A manufacturing process includes: mixing a hydrophilic polymer and alfuzosin to provide a blend; granulating the blend to provide granules; drying the granules on a dryer to provide dried granules; sizing the dried granules to provide sized granules; mixing the sized granules with a lubricant to obtain a mixture; and compressing the mixture to obtain a tablet. A method of treating benign prostatic hyperplasia, includes administering to a patient the composition or unit dosage form once a day.

The invention relates to an application of an alfuzosin compound in prevention or treatment of Alzheimer's disease and related diseases, and belongs to the technical field of medicines. The alfuzosincompound has the effects of improving mitochondrial metabolism, degrading accumulation of various pathological proteins and improving vascular endothelial cell functions. The invention provides a newpharmaceutical application of the alfuzosin compound. The new pharmaceutical application can provide a new choice for treatment of clinical related diseases. Alfuzosin, an alfuzosin isomers, TZ-md andAZ-md can be beneficially applied to Alzheimer's disease and related complications, such as seeing and hearing impairment, anemia, blood pressure instability, insomnia, depression, limb dysfunction,malnutrition, weakness, dizziness, gait instability and the like, and diseases related to protein accumulation and metabolic disorder, such as Huntington's disease, amyotrophic lateral sclerosis, dementia with Lewis bodies, multi-system atrophy and the like.

The invention relates to application of Alfuzosin to treating or preventing the Parkinson's disease and related diseases. The invention belongs to the technical field of medicines, and relates to theapplication of Alfuzosin newly-prepared medicines, in particular to application of the Alfuzosin to treating or preventing the Parkinson's disease and related diseases.

The invention relates to a specific combination of two active agents: udenafil and one of alfuzosin and oxybutynin and its use for the treatment of overactive bladder.

The invention discloses alfuzosin hydrochloride sustained release tablets and a preparation method thereof. The sustained release tablets are prepared by adopting the following raw materials: alfuzosin hydrochloride, hydroxypropyl methylcellulose and lubricating agents, and adopting the processing steps of material preparation, mixing, granulation, total blending, tabletting, aluminium-plastic packaging, and the like. The alfuzosin hydrochloride sustained release tablets have the beneficial effects that the alfuzosin hydrochloride sustained release tablets are mainly used for treating functional symptoms of benign prostatic hyperplasia; the more novel sustained release preparation is adopted; sustained release refers to that the rate of absorption of the medicines into bodies is reduced by reducing the rate of release of the medicines from the dosage form, thus achieving the more stable treatment effects; the effective blood concentration can be maintained in a longer time, the toxic and side effects of the medicines can be also reduced and the medicine safety is improved; the alfuzosin hydrochloride sustained release tablets are convenient to use, are especially suitable for chronic disease patients who take medicines for a long term, and have the effect of improving the compliance of the patients; alfuzosin hydrochloride sustained release tablets have the advantages of good medicine stability, convenience in packaging, transportation and storage, and the like; and the preparation method is simple and practicable and is suitable for industrial production.

The present invention relates to novel N-[3-[(4-acyl- / aroyl-substituted amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide derivatives, and a process for the preparation thereof. The novel compounds are useful for preparing alfuzosin or a pharmaceutically acceptable salt thereof in high yield and purity.

The invention relates to processes for the preparation of alfuzosin or pharmaceutically acceptable salts thereof in high purity. More particularly, it relates to the preparation of pure crystalline alfuzosin base. The invention also relates to pharmaceutical compositions that include the pure alfuzosin or a pharmaceutically acceptable salt thereof.

The invention discloses an Alfuzosin preparing method, adopting 3- halogenated propylamine as raw material, making condensation reaction with 2-tetrahydrofurioic acid or 2-tetrahydro furoyl chloride and obtaining intermediate N-3-halogenated propyl-2-tetrahydro furoyl amine, which then condenses with methylamine to obtain intermediate N-3-methylamino propyl-2-tetrahydro furoyl amine, which then condenses with 2-chloro-4-amino-6, 7-dimethoxy-quinazoline to obtain Alfuzosin. And the mentioned synthesis method is simple, low-cost, and has reacting conditions easy to control, high product yield and relatively improved quality of product, suitable for industrialized production.

A monolithic composition includes alfuzosin in a polymeric matrix adapted to release 13-33% of the alfuzosin within 2 hours, 40-60% of the alfuzosin within 7 hours, and greater than 80% of the alfuzosin within 20 hours of administration. A unit dosage form includes: a heterogeneous mixture of alfuzosin hydrochloride, lactose monohydrate, hydroxypropylmethylcellulose, polyvinylpyrrolidone and magnesium stearate, wherein the heterogeneous mixture is heterogeneously distributed throughout the unit dosage form. A manufacturing process includes: mixing a hydrophilic polymer and alfuzosin to provide a blend; granulating the blend to provide granules; drying the granules on a dryer to provide dried granules; sizing the dried granules to provide sized granules; mixing the sized granules with a lubricant to obtain a mixture; and compressing the mixture to obtain a tablet. A method of treating benign prostatic hyperplasia, includes administering to a patient the composition or unit dosage form once a day.

The invention relates to processes for the preparation of alfuzosin or pharmaceutically acceptable salts thereof in high purity. More particularly, it relates to the preparation of pure crystalline alfuzosin base. The invention also relates to pharmaceutical compositions that include the pure alfuzosin or a pharmaceutically acceptable salt thereof.

The invention relates to a specific combination of two active agents: udenafil and one of alfuzosin and oxybutynin and its use for the treatment of overactive bladder.

The invention belongs to the field of sustained release preparations, and particularly relates to an alfuzosin hydrochloride sustained release preparation and a preparation method thereof. The alfuzosin hydrochloride sustained-release preparation provided by the invention comprises a drug-loaded pellet, a sustained-release coating layer and a pharmaceutic adjuvant layer, and the drug-loaded pellet comprises alfuzosin hydrochloride, a filler, a plasticizer, a sustained-release framework material, a lubricant and a stabilizer; the sustained-release coating layer comprises a film-forming material, a plasticizer, a lubricant and purified water. The pharmaceutic adjuvant layer comprises a filling agent, a disintegrating agent, a flavoring agent, a lubricating agent and a flow aid. The preparation of the alfuzosin hydrochloride orally disintegrating tablet has the characteristics that the alfuzosin hydrochloride orally disintegrating tablet can be disintegrated or dissolved without water in the oral cavity, has the characteristics of convenience in taking, quick absorption and high bioavailability, and can improve the medication compliance of patients and increase the clinical medication choices of doctors for different patients.

The invention discloses an Alfuzosin preparing method, adopting 3- halogenated propylamine as raw material, making condensation reaction with 2-tetrahydrofurioic acid or 2-tetrahydro furoyl chloride and obtaining intermediate N-3-halogenated propyl-2-tetrahydro furoyl amine, which then condenses with methylamine to obtain intermediate N-3-methylamino propyl-2-tetrahydro furoyl amine, which then condenses with 2-chloro-4-amino-6, 7-dimethoxy-quinazoline to obtain Alfuzosin. And the mentioned synthesis method is simple, low-cost, and has reacting conditions easy to control, high product yield and relatively improved quality of product, suitable for industrialized production.

The invention relates to a medicinal composition for treating benign prostatic hyperplasia. The medicinal can be tablets, capsules, granules and the like prepared from alfuzosin or pharmaceutically acceptable salt thereof with effective dosage and plantain seed alcohol extract in a mass ratio of 1:(1-10000) by the amount of alfuzosin. Pharmacological researches on the medicinal composition discover that the medicinal composition for treating benign prostatic hyperplasia has perfect treatment effect, and can remarkably inhibit benign prostatic hyperplasia of a rat subjected to orchiectomy. The alfuzosin or pharmaceutically acceptable salt and the plantain seed alcohol extract have a synergetic effect, and achieve an unexpected technical effect.

The invention belongs to the technical field of medical drugs, and particularly relates to a combined tablet for treating erectile dysfunction and premature ejaculation, and the combined tablet is prepared from the following raw materials in parts by weight: tadalafil, dapoxetine hydrochloride, alfuzosin, a food-grade binder, a disintegrating agent and a food-grade filler. According to the invention, dapoxetine hydrochloride is filled into the capsule, tadalafil and alfuzosin are compressed around the nucleus to be prepared into tablets, and the tablets are used for treating patients with erectile dysfunction, premature ejaculation and coexistence of the erectile dysfunction and the premature ejaculation, have the advantages of being good in effect, small in dosage, high in tolerance, few in side effect and the like and have good practicability.